Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/31/2025

Physiological Effects of the Valsalva Maneuver and Squatting

Introduction to Physiological Effects

  • The Valsalva maneuver and squatting produce opposite physiological effects on the cardiovascular system, with the Valsalva maneuver reducing venous return and cardiac output, while squatting increases them, making them useful for different clinical applications, as noted by the European Society of Cardiology 1

Phases of the Valsalva Maneuver

  • The Valsalva maneuver consists of four distinct phases:
  • In patients with heart failure, the normal four-phase response is altered, showing either an "absent overshoot" pattern or a "square wave" pattern where blood pressure remains elevated throughout the strain period, according to the European Society of Cardiology 1

Diagnostic and Therapeutic Uses

  • The Valsalva maneuver is used as a diagnostic tool to evaluate autonomic function and heart failure severity, as recommended by the European Society of Cardiology 1
  • The Valsalva maneuver and squatting are used as provocative testing to uncover dynamic left ventricular outflow tract obstruction in hypertrophic cardiomyopathy, as suggested by the American College of Cardiology 3, 4, and the American Heart Association 5
  • Vagal maneuvers, including the Valsalva maneuver and the cold stimulus technique, are recommended as the first-line treatment for supraventricular tachycardia, according to the American College of Cardiology/American Heart Association guidelines 6, 7

Clinical Safety Profile

  • The Valsalva maneuver is contraindicated in certain conditions, such as severe conduction abnormalities and sinus node dysfunction, while squatting is generally safer but may be difficult for patients with mobility issues, as noted by the European Society of Cardiology 1
  • Adenosine is contraindicated in second or third-degree AV block and sick sinus syndrome, and should be avoided in patients with severe asthma due to risk of bronchospasm, as recommended by the American College of Cardiology 6, 7
  • Calcium channel blockers should be avoided in patients with pre-excited atrial fibrillation, heart failure, or hypotension, as recommended by the American College of Cardiology 6, 7

Recommendations for Clinical Practice

  • When performing provocative testing for hypertrophic cardiomyopathy, both Valsalva and squat-to-stand maneuvers are recommended to uncover dynamic left ventricular outflow tract obstruction, as recommended by the American College of Cardiology 4 and the American Heart Association 5
  • The Valsalva maneuver should be performed with standardized technique (15 seconds, 40 mmHg pressure) for optimal diagnostic value, as suggested by the European Society of Cardiology 2, 1
  • The Valsalva maneuver should be performed with the patient in a supine position, bearing down against a closed glottis for 15 seconds with a pressure of 40 mmHg, followed by normal breathing, as recommended by the European Society of Cardiology and supported by the American Heart Association 2, 6
  • Monitoring with beat-to-beat continuous non-invasive BP measurement and ECG is essential during the test, as suggested by the European Society of Cardiology 2
  • The American College of Cardiology/American Heart Association guidelines recommend a standard Valsalva maneuver with a patient in a supine position bearing down against a closed glottis for 10-30 seconds, generating pressure equivalent to at least 30-40 mmHg 6, 7
  • Adenosine is recommended as a second-line treatment for supraventricular tachycardia, with a dose of 6 mg rapid IV push, which may be repeated with 12 mg if needed, as recommended by the American College of Cardiology 6, 7
  • IV calcium channel blockers (diltiazem, verapamil) or beta blockers are recommended as third-line treatment, and synchronized cardioversion is recommended as a fourth-line treatment for hemodynamically unstable patients or when medications fail, as recommended by the American College of Cardiology/American Heart Association guidelines 6, 7

Special Considerations

  • In pregnant patients, the same duration (10-30 seconds) is recommended for the Valsalva maneuver, as recommended by the American College of Cardiology 6
  • The American College of Cardiology recommends assessing if the patient is taking gender-affirming hormone therapy, which could potentially affect cardiovascular parameters, although no specific evidence suggests SVT treatment should differ in transgender males 6, 7

Potential Pitfalls

  • Insufficient pressure (less than 40 mmHg) and inadequate duration (less than 15 seconds) can reduce the effectiveness of the Valsalva maneuver, as warned by the European Society of Cardiology 2
  • Applying pressure to the eyeball is a dangerous technique that has been abandoned, as warned by the American Heart Association 6
  • Unmonitored performance of the Valsalva maneuver can be risky, and monitoring of hemodynamic changes during the test is recommended when possible, as suggested by the European Society of Cardiology 2
  • Misidentifying the rhythm, using verapamil or diltiazem in patients with pre-excited atrial fibrillation, and failing to prepare for potential adverse effects of adenosine are potential pitfalls to avoid, as highlighted by the American College of Cardiology and American Heart Association guidelines 6, 7

REFERENCES